IDEAYA Biosciences, Inc. (IDYA) News
Track canonical SquawkNews coverage tagged to IDYA, IDEAYA Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Weekly Recap: Stock option grants and Dr. Michael White promotion
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) bolstered its leadership and talent pool in late September 2026, promoting Dr. Michael White to President, R&D to steer its oncology precision—medicine and ADC programs while granti
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
IDEAYA Biosciences, Inc. (IDYA) Promotes Dr. Michael White to President, R&D
IDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective Sept. 28, 2026.Material DetailsContext by AI AnalystThis is a management evolution reinforcing
NEWS | Sep 28, 2026, 10:01 AM UTC
L
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 // -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the pro
NEWS | Sep 28, 2026, 10:00 AM UTC
L
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 // -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, o
NEWS | Sep 25, 2026, 10:00 AM UTC
M
IDeYA darovasertib NDA near completion; pipeline expands via new collaborations
IDEAYA says its darovasertib final NDA submission is imminent after positive FDA feedback, with new data to be presented at ESMO. Pipeline expansion includes a phase III DLL3 ADC trial and new Roche, PRMT5 and CDKN2A col
REGULATION | Sep 09, 2026, 05:20 PM UTC
L
IDYA darovasertib NDA nearing completion amid FDA feedback
IDEAYA Bio (IDYA) says a final NDA submission for darovasertib is imminent, with positive FDA feedback potentially enabling an all-comers label. Clinical and pipeline updates are slated for ESMO.
REGULATION | Sep 09, 2026, 04:29 PM UTC
L
IDEAYA Biosciences price target raised to $57 by Guggenheim
Guggenheim raised its price target on IDEAYA Biosciences to $57.00 per share from $54.00, according to Benzinga ratings coverage.
EQUITY | Sep 09, 2026, 01:21 PM UTC
M
IDYA and Servier dose first patient in OptimUM-11 Phase 3 uveal melanoma trial
IDEAYA Biosciences and Servier announced the first patient was dosed in OptimUM-11, a Phase 3 registrational trial evaluating darovasertib and crizotinib as adjuvant therapy for uveal melanoma.
EQUITY | Sep 09, 2026, 10:00 AM UTC
M
IDYA darovasertib nears NDA completion toward major U.S. milestones
Darovasertib is nearing NDA completion for metastatic uveal melanoma, with a potential U.S. launch in the first half of next year. PRMT5 and DLL3 pipeline assets are also advancing toward major data readouts and trial in
EQUITY | Sep 08, 2026, 07:59 PM UTC
L
Citizens maintains IDEAYA Biosciences price target at $42
Citizens maintained a $42.00 per-share price target for IDEAYA Biosciences.
EQUITY | Sep 01, 2026, 01:42 PM UTC
L
IDEAYA Biosciences to host London Investor R&D Day
IDEAYA Biosciences announced a London Investor R&D Day and plans to participate in September 2026 investor conferences.
EQUITY | Sep 01, 2026, 10:00 AM UTC
L
IDEAYA Biosciences announces Nasdaq Rule 5635(c)(4) inducement grants
IDEAYA Biosciences announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Aug 28, 2026, 10:01 AM UTC
H
Ideaya Biosciences, Genentech launch Phase 1 combo trial in KRAS G12D PDAC
Ideaya Biosciences (IDYA) announces a clinical collaboration with Genentech to sponsor a jointly governed trial and plan a Phase 1 combination cohort with Roche’s rg6505 in mtap-deleted, KRAS G12D mutant pancreatic cance
EQUITY | Aug 19, 2026, 10:34 AM UTC
L
IDEAYA Biosciences enters clinical collaboration with Genentech
IDEAYA Biosciences (IDYA) announces a clinical collaboration with Genentech focused on MTAP-deleted KRAS G12D-mutant pancreatic cancer.
EQUITY | Aug 19, 2026, 10:00 AM UTC
L
IDYA IDYA - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDYA IDYA - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 04, 2026, 10:00 AM UTC
L
IDEAYA Biosciences Announces Inducement Grants
IDEAYA Biosciences grants inducement awards
EQUITY | Jul 31, 2026, 10:00 AM UTC
L
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion in the phase 1/2 study in mtap-deleted pancreatic and lung cancers
EQUITY | Jul 27, 2026, 10:27 AM UTC
L
Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing
() -- Briseno Andres Ruiz, Chief Accounting Officer, on July 07, 2026, sold 9,550 shares in Ideaya Biosciences (IDYA) for $382,131. Following the Form 4 filing with the SEC, Ruiz has control over a total of 26,466 common
REGULATION | Jul 09, 2026, 09:02 PM UTC